Lactobacillus reuteri SKLAN202402ZF inhibited by early-life lincomycin exposure alleviate intestinal damage and inflammation sensitivity.

BACKGROUND: Early-life lincomycin and related antibiotics exposure affected gut microbiota composition and intestinal health, but which microbes play a dominant role in this process remains unclear. RESULTS: Lactobacillus reuteri was suppressed in piglets exposed to lincomycin. Meanwhile, early-life lincomycin exposure caused intestinal morphological damage and decreased the expression of Claudin-1, Occludin, and ZO-1. Mice transplanted with lincomycin-exposed piglet fecal microbiota showed more severe inflammation and weight loss after LPS infection, and decreased colon Lactobacillus abundance. Furthermore, mice supplemented with Lactobacillus reuteri SKLAN202402ZF showed reduced lincomycin-related intestinal damage and inflammation after LPS infection. Specifically, Lactobacillus reuteri SKLAN202402ZF inhibits the expression of TLR4, MyD88, and NLRP3, and thus reduced the release of inflammatory factors such as IL-1β, IL-18, IL-17. CONCLUSIONS: Lincomycin exposure affects the composition of gut microbes and increases subsequent susceptibility to LPS, while Lactobacillus reuteri SKLAN202402ZF has protective potential against antibiotic- associated intestinal inflammation.